Uncommon fatty acids and cardiometabolic health by Li, Kelei et al.
 DRO  
Deakin Research Online, 
Deakin University’s Research Repository  Deakin University CRICOS Provider Code: 00113B 
Uncommon fatty acids and cardiometabolic health 
Citation:  
Li, Kelei, Sinclair, Andrew J., Zhao, Feng and Li, Duo 2018, Uncommon fatty acids and 
cardiometabolic health, Nutrients, vol. 10, no. 10, pp. 1-14. 
DOI: 10.3390/nu10101559  
 
 
 
 
 
© 2018, The Authors 
Reproduced by Deakin University under the terms of the Creative Commons Attribution Licence 
 
 
 
 
 
 
Downloaded from DRO:  
http://hdl.handle.net/10536/DRO/DU:30114730  
nutrients
Review
Uncommon Fatty Acids and Cardiometabolic Health
Kelei Li 1, Andrew J. Sinclair 2,3, Feng Zhao 1 and Duo Li 1,3,*
1 Institute of Nutrition and Health, Qingdao University, Qingdao 266021, China; likelei@qdu.edu.cn (K.L.);
fzhao@qdu.edu.cn (F.Z.)
2 Faculty of Health, Deakin University, Locked Bag 20000, Geelong, VIC 3220, Australia;
andrew.sinclair@deakin.edu.au
3 Department of Nutrition, Dietetics and Food, Monash University, Notting Hill, VIC 3168, Australia
* Correspondence: duoli@qdu.edu.cn; Tel.: +86-532-8299-1018
Received: 7 September 2018; Accepted: 18 October 2018; Published: 20 October 2018


Abstract: Cardiovascular disease (CVD) is a major cause of mortality. The effects of
several unsaturated fatty acids on cardiometabolic health, such as eicosapentaenoic acid (EPA)
docosahexaenoic acid (DHA), α linolenic acid (ALA), linoleic acid (LA), and oleic acid (OA) have
received much attention in past years. In addition, results from recent studies revealed that several
other uncommon fatty acids (fatty acids present at a low content or else not contained in usual
foods), such as furan fatty acids, n-3 docosapentaenoic acid (DPA), and conjugated fatty acids, also
have favorable effects on cardiometabolic health. In the present report, we searched the literature in
PubMed, Embase, and the Cochrane Library to review the research progress on anti-CVD effect of
these uncommon fatty acids. DPA has a favorable effect on cardiometabolic health in a different way
to other long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFAs), such as EPA and DHA. Furan
fatty acids and conjugated linolenic acid (CLNA) may be potential bioactive fatty acids beneficial
for cardiometabolic health, but evidence from intervention studies in humans is still limited, and
well-designed clinical trials are required. The favorable effects of conjugated linoleic acid (CLA) on
cardiometabolic health observed in animal or in vitro cannot be replicated in humans. However, most
intervention studies in humans concerning CLA have only evaluated its effect on cardiometabolic
risk factors but not its direct effect on risk of CVD, and randomized controlled trials (RCTs) will
be required to clarify this point. However, several difficulties and limitations exist for conducting
RCTs to evaluate the effect of these fatty acids on cardiometabolic health, especially the high costs
for purifying the fatty acids from natural sources. This review provides a basis for better nutritional
prevention and therapy of CVD.
Keywords: furan fatty acids; docosapentaenoic acid; conjugated fatty acids; cardiovascular disease;
metabolic disease; blood lipids; inflammation; antioxidant
1. Introduction
Cardiovascular disease (CVD) is a major cause of mortality [1]. In addition to genetic factors,
dyslipidemia [2], poor glycemic control [3], oxidative stress [4], inflammation [5], obesity [6],
hyperhomocysteinemia [7], smoking [8], lack of exercise [8], and dietary factors [8] are all related to
the development of CVD.
Fatty acids are important structural components of biological membranes and an energy source
for living organism. In addition, they also play an important role in regulating many physiological
processes, such as inflammation, glycemic control, lipid metabolism and oxidative stress. All these
physiological processes are closely related to the development of CVD and metabolic disorders. The
beneficial effect of several unsaturated fatty acids, such as eicosapentaenoic acid (EPA) docosahexaenoic
acid (DHA), α linolenic acid (ALA), linoleic acid (LA), and oleic acid (OA), on cardiometabolic health
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has been given much attention [9–19]. However, the effect of several other uncommon fatty acids
(fatty acids present at a low content or else not contained in usual foods) on cardiometabolic health,
such as furan fatty acids, n-3 docosapentaenoic acid (DPA), and conjugated fatty acids, is also worthy
of attention. In the present review, we searched PubMed, Embase, and the Cochrane Library for the
terms (docosapentaenoic acid OR n-3 polyunsaturated fatty acids OR DPA OR furan fatty acids OR
CMPF OR conjugated linolenic acid OR conjugated linoleic acid OR conjugated fatty acid OR CLNA
OR CLA) in combination with (cardiometabolic health OR cardiovascular disease OR CVD OR blood
lipids OR diabetes mellitus OR glucose metabolism OR oxidative stress OR inflammation) up to July
2018, to review the research progress on the effect of these uncommon fatty acids on cardiometabolic
health. Studies in humans, animals or in vitro evaluating the relationship between uncommon fatty
acids (furan fatty acids, conjugated fatty acids or DPA) and cardiometabolic health were included in
the present review. The review should provide a basis for better nutritional prevention and therapy of
CVD and metabolic disorders.
2. Furan Fatty Acids and Cardiometabolic Health
2.1. Origin of Furan Fatty Acids
Naturally occurring furan fatty acids are a family of fatty acids consisting of a furan ring with
a fatty acid chain on the α1-position, a short straight alkyl group on the α2-position, a methyl
group on the β1-position, and either a methyl group or a hydrogen atom on the β2-position [20].
Structures of the most abundant furan fatty acids are shown in Figure 1. Furan fatty acids have
been found in different biological species, in low concentrations, including marine and freshwater
fish [21], plants [22], algae [23,24], crustaceans [25,26], mammals [27], human tissues [28], fungi [29],
ascidian [30], bacteria [31], bivalves [32], and echinoidea [33]. Furan fatty acids are mainly enriched
in cholesterol ester and fraction of triacylglycerol (TAG) in liver of mammals, but occur mainly in
phosphatidylcholine (PC) and phosphatidylethanolamine (PE) in plasma [34].
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2.2. Evidence from Human Studies
In addition to EPA and DHA, furan fatty acids may be another bioactive constituent of
marine food and its oil product beneficial for cardiometabolic health despite its low concentration
(around 1% in some species of fish [21,28]). Fish oil consumption significantly increased
3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF), a metabolite of common furan fatty
acids, by 3-fold and 5 to 6-fold in serum and urine of humans, respectively [36]. Our recent
randomized controlled trial (RCT) in subjects with type 2 diabetes mellitus (T2DM) indicated that fish
oil consumption significantly increased the serum CMPF level, and most importantly, the change of
CMPF during intervention was negatively correlated with the change of plasma TAG levels [37]. In
another randomized crossover study, a multifunctional diet (MFD) formulated according to the Nordic
Nutrition Recommendations improved serum total cholesterol (TC), low density lipoprotein cholesterol
(LDLC), triacylglycerol (TAG), ratios of LDL to high density lipoprotein (HDL) and apolipoprotein
B (ApoB) to ApoA1, glycated hemoglobin (HbA1c), C-reactive protein (CRP) and systolic blood
pressure [38]. Metabolomics analysis indicated that this MFD significantly increased plasma level of
four furan fatty acids, including CMPF, 3,4-dimethyl-5-pentyl-2-furanpropanoic acid (a furan fatty
acids have been identified in crayfish), and furan fatty acids with molecular weights of 226.084 and
252.172 (accurate structure was not confirmed). Furthermore, a strong inverse correlation of CMPF
and 3,4-dimethyl-5-pentyl-2-furanpropanoic acid with TC, LDLC, and the LDLC to HDLC ratio was
observed [38]. Furan fatty acids may also have an anti-inflammatory effect: The New Zealand green
lipped mussel contains a certain amount of furan fatty acids [32], and our previous RCT indicated
a lipid extract from mussels effectively improved clinical conditions of patients with rheumatoid
arthritis, significantly decreased levels of tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β) and
prostaglandin E2 (PGE2), and significantly increased levels of IL-10 [39].
However, until now, no clinical trials have been conducted to evaluate the effect of furan fatty
acids with relatively high purity on cardiometabolic health because they are usually difficult to separate
in quantity and high purity from other fatty acids. One previous study indicated that starvation could
dramatically increase the weight percentage of furan fatty acids in total lipids of cod liver by more than
34% [21]. A method for isolation of furan fatty acids from fish lipids has been reported, and the process
included: lipid extraction by chloroform and methanol (2:1), methylation of fatty acids, hydrogenation
of common straight-chain unsaturated fatty acid methyl esters, and removal of saturated fatty acid
methyl esters by crystallization as urea complexes [35]. In addition to isolation of furan fatty acids
from lipids of food, artificial synthesis is another option to obtain furan fatty acids with relatively high
degree of purity [40].
2.3. Evidence from Animal and In Vitro Studies
One recently published animal study indicated that purified CMPF supplementation improved
insulin sensitivity, increased beta-oxidation, reduced lipogenic gene expression, and ameliorated
steatosis [41]. This suggested that CMPF has a favorable metabolic effect. However, a contradictory
result concerning the effect of CMPF on glucose metabolism was observed by another animal study,
including glucose intolerance, impaired glucose-stimulated insulin secretion, and decreased glucose
utilization [42]. Sand et al. extracted furan fatty acids from northern pike (Esox lucius) testes, and
supplementation of furan fatty acids to rats led to the appearance of CMPF in urine, indicating
that CMPF was a metabolite of common furan fatty acids [43]. Wakimoto et al. extracted furan
fatty acids (predominantly F4 and F6) from mussels and compared their anti-inflammatory effect
with EPA, commercially available F6, and the anti-inflammatory drug Naproxen in a rat model of
adjuvant-induced arthritis, and found that furan fatty acids extracted from mussels had comparable
anti-inflammatory effect with Naproxen and commercially available F6; the anti-inflammatory effect of
furan fatty acids was more potent than that of EPA [32]. The anti-inflammatory effect of a lipid extract
from mussel was also observed in our previous animal study which found that a lipid extract from
mussel had an equivalent protective effect to fish oil on intestinal integrity after lipopolysaccharide
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(LPS) challenge in mice, by increasing the expression of anti-inflammatory cytokine IL-10, decreasing
the expression of pro-inflammatory cytokines TNF-α and IL-1β and downregulating toll-like receptor
4 (TLR-4) signal pathway [39]. These results indicated that furan fatty acids, long neglected, might be
one bioactive component responsible for the anti-inflammatory effect of lipid products of marine food.
Okada et al. synthesized four kinds of furan fatty acids, F2, F3, F6, and 9,12-epoxyoctadeca-9,11-dienoic
acid (NMF), and found that tetra-alkyl substituted furan fatty acids (F3 and F6) had the best antioxidant
activity in vitro by decomposing hydroperoxides and scavenging peroxyl radicals; the antioxidant
activity of tri-alkyl substituted compound (F2) was about 50% as effective as the tetra-alkyl substituted
one, while di-alkyl substituted one (NMF) revealed no significant activity [44]. Another in vitro study
by Okada et al. compared the hydroxyl radical scavenging activity of artificially synthesized furan
fatty acids (F2, F3, and NMF) with other common hydroxyl radical scavengers, and found that the
hydroxyl radical scavenging activity of furan fatty acids was better than mannitol and ethanol, and was
comparable with that of histidine and dimethyl sulfoxide (DMSO) [45]. Lipid oxidation is an important
aspect in the pathogenesis for CVD [46]. Therefore, furan fatty acids, because of their antioxidant
activity, may also play a role in protecting against aspects of CVD.
2.4. Brief Summary
Evidence from previous studies implied a favorable effect of furan fatty acids on cardiometabolic
health. Clinical trials are required to confirm the direct effect of furan fatty acids on cardiometabolic
health by using purified furan fatty acids as treatment.
3. DPA and Cardiometabolic Health
3.1. Origin of DPA
DPA is a long chain n-3 polyunsaturated fatty acid (LC n-3 PUFA) widely existing in marine
foods and fish oils, together with EPA and DHA. The structures of DPA, EPA, and DHA are shown in
Figure 2. The content of DPA in most fish is typically much less than that of EPA and DHA, and in
salmon flesh, fish oil, and seal oil the levels are about 0.3%, 2–5%, and 4–5%, respectively [47]. One
previous study dramatically increased DPA content in a marine fish, nibe croaker, from 1.8% to 4.1%
by addition of an elongase gene to the fish [48].
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docosahexaenoic acid (DHA).
3.2. Evidence from Human Studies
Most previous studies evaluating the effect of LC n-3 PUFA on cardiometabolic health did not
discriminate between the effect of EPA, DHA, and DPA. Results from recent studies indicated that
DPA could also influence cardiometabolic health. Our previous meta-analysis based on 10 prospective
cohort studies in 20,460 individuals indicated that the risk of stroke was negatively associated with
circulating level of DPA (relative risk (RR) 0.74, 95% confidence interval (CI) 0.60 to 0.92) and DHA
(RR 0.78, 95% CI 0.65 to 0.94), but not EPA (RR 0.95, 95% CI 0.82 to 1.12) [49]. Dose–response analysis
indicated that 1% increment of DPA and DHA proportions in circulating blood was associated with
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25% (RR 0.75, 95% CI 0.64 to 0.87) and 11% (RR 0.89, 95% CI 0.83 to 0.95) reduced risk of stroke,
respectively [49]. One meta-analysis based on prospective cohort studies indicated that coronary risk
was negatively associated with circulating levels of DPA (RR 0.64, 95% CI 0.47 to 0.87, 7155 subjects in
four studies) [50]. Evidence from observational studies indicated that the circulating DPA level was
also negatively associated with the risk of cardiovascular mortality (hazard ratio (HR) 0.68, 95% CI
0.52 to 0.89) [51], sudden cardiac death (odds ratio (OR) 0.70, 95% CI 0.51 to 0.97) [52], heart failure
(OR 0.81, 95% CI 0.68–0.95) and peripheral arterial disease (OR 0.61, 95% CI 0.45 to 0.82) [53] as well as
carotid intimal–medial thickness (β = −0.0002 ± 0.0007 (standard error), p = 0.037) [54].
Our previous double blind crossover study found that pure DPA supplementation could
significantly reduce postprandial plasma chylomicronemia compared with pure EPA or olive oil
supplementation in healthy subjects [55]. Another crossover study found that compared with EPA
alone, EPA + DPA supplementation could significantly lower TAG, TC, non-high-density lipoprotein
cholesterol, very low-density lipoprotein cholesterol (VLDLC), ApoC3, and proprotein convertase
subtilisin kexin type 9 (PCSK9) in subjects with severe hypertriglyceridemia [56]. This trial also
reported that EPA + DPA supplementation rather than EPA alone could significantly reduce nile
red staining of lipids in monocytes, and that both EPA + DPA and EPA alone significantly reduce
monocytes surface markers CD11c, CD36, and CCR5, indicating that DPA might protect against
atherosclerosis by inhibiting foamy monocyte formation and modulating monocyte phenotype [57]. In
addition, DPA can modulate lipid mediator profile in a different way compared with EPA: in a crossover
study, DPA supplementation increased 19,20-dihydroxy-DPA (19,20-DiHDoPE), 7,17-DiHDoPE, and
15-keto-prostaglandin E2, while EPA increased monohydroxy-eicosapentaenoic acids (HEPEs), and
there was no overlap in PUFA metabolites formed after DPA and EPA supplementation [58]. One
RCT found that EPA + DPA supplementation dose-dependently increased erythrocyte membrane DPA
content, and DPA level was inversely associated with serum CRP level. A cohort study in 2547 children
with elevated risk of type 1 diabetes indicated that erythrocyte membrane DPA content but not EPA or
DHA was negatively associated with the risk of islet autoimmunity [59]. Our cross-sectional study in
healthy subjects indicated that after adjusting for potential confounding factors, platelet phospholipid
DPA content but not EPA was inversely correlated with mean platelet volume, an independent risk
factor for acute myocardial infarction [60].
3.3. Evidence from Animal and In Vitro Studies
In a rat model of rheumatoid arthritis, DPA showed a comparable reducing effect with EPA
on the progression and severity of arthritic disease as well as pro-inflammatory cytokines, such as
IL-17A, IL-1β, IL-6, and TNFα [61]. In addition, DPA and EPA both significantly down-regulated
the activation of mitogen-activated protein kinases (p38 MAPK) and nuclear factor-kappa B (NF-κB)
pathways and decreased the expression of cyclooxygenase-2 (COX-2), matrix metalloproteinase-2
(MMP-2) and MMP-9 [61]. This can help explain the mechanism for their anti-inflammatory effect.
Moreover, pro-resolving mediators derived from DPA can also contribute to its anti-inflammatory
effect, but the types of pro-resolving mediators derived from DPA were different from those derived
from other LC n-3 PUFA, such as EPA and DHA [62]. In mice fed a high-fat diet, purified DPA,
EPA, or DHA supplementation improved serum TC, glucose, and liver cholesterol content; only
DPA improved insulin resistance rather than EPA or DHA. DPA and DHA but not EPA prevented
decreased serum adiponectin and increased serum alanine aminotransferase (ALT) [63]. Either high-fat
diet or high-fructose diet significantly decreased plasma DPA and DHA level in rats, and both LC
n-3 PUFAs were positively associated with insulin sensitivity [64]. Our previous study in rat liver
cells indicated that DPA could down-regulate a series of genes involved in fat synthesis, including
sterol-regulatory element-binding protein-1c (SREBP-1c), 3-hydroxy-3-methyl-glutaryl-coenzyme A
reductase (HMG-CoA reductase), acetyl coenzyme A carboxylase (ACC-1), and fatty acid synthase
(FASn) [65]. This result can help explain the mechanism for the protecting effect of DPA against
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hypertriglyceridemia. Reduced platelet aggregation by DPA was also observed in our previous in vitro
study [66].
3.4. Brief Summary
DPA has a favorable effect on cardiometabolic health in a different way to the other LC n-3 PUFAs,
such as EPA and DHA. However, few intervention studies in humans have been conducted to evaluate
the direct effect of DPA on risk of CVD. Well-designed RCTs should be conducted by using purified
DPA as treatment to clarify this point.
4. Conjugated Fatty Acids and Cardiometabolic Health
4.1. Origin of Conjugated Fatty Acids
Conjugated fatty acids is the general term for positional and geometric isomers of polyunsaturated
fatty acids with conjugated double bonds [67]. The most common conjugated fatty acids are conjugated
linoleic acids (CLAs), such as cis-9,trans-11 CLA and trans-10,cis-12 CLA, and conjugated linolenic
acids (CLNAs), such as α-eleostearic acid, punicic acid, and jacaric acid. cis-9,trans-11 CLA is the
main naturally occurring isomer of CLA, and it was first found as an intermediate for the conversion
from PUFA to saturated stearic acid by rumen bacteria [68]. This explained its presence in food from
ruminant-animal origin, such as beef, sheep and goat meat and dairy products [67]. In addition, CLA
has also been found in low proportions in some plant oils and seafood [69]. CLNA naturally occurs in
plant seeds, such as tung seed, bitter gourd seed, snake gourd seed, pomegranate seed, trichosanthes
seed, pot marigold seed, jacaranda seed, and catalpa seed [70–72]. Several studies in humans and
animals indicated that CLNA could be metabolized into CLA in vivo [73,74]. The structures of the
most common conjugated fatty acids are shown in Figure 3.
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4.2. CLA and Cardiometabolic Health
4.2.1. Evidence from Human Studies
Few significant effects of CLA on CVD and its risk factors have been observed in human
studies. Only one case-control study reported a significant negative association between cis-9,trans-11
CLA in adipose tissue and risk of myocardial infarction [75]. One RCT indicated that 6-month
supplementation of cis-9,trans-11 CLA had no significant influence on blood lipids, glucose, CRP,
blood pressure, insulin resistance, body composition and 10-year absolute risk of fatal CVD calculated
by the European Systematic Coronary Risk Evaluation (SCORE) formula in overweight and obese
subjects [76]. Consistent results concerning CVD risk factors were also observed in another two RCTs
in healthy subjects and patients with atherosclerosis [77,78]. In addition, results from RCTs even
indicated that cis-9,trans-11 CLA consumption could increase lipid peroxidation [77,79]. One RCT
found that supplementation of another isomer of CLA, trans-10,cis-12 CLA, significantly increased CRP
as well as lipid peroxidation [80]. Only one RCT reported a significant lowering effect of CLA (mixture
of cis-9,trans-11 CLA and trans-10,cis-12 CLA, 50:50) on CRP in patients with atherosclerosis [81].
4.2.2. Evidence from Animal and in Vitro Studies
Lee et al. first reported that CLA (the isomer of CLA used was not reported) could significantly
decrease TC, LDLC, TAG, the ratios of LDLC to HDLC and TC to HDLC and led to less atherosclerosis
in rabbits [82]. The protective effect of CLA (cis-9,trans-11 CLA, trans-10,cis-12 CLA or their mixture)
against atherosclerosis was also observed in other animal studies [83–85]. A more recent study
in mice indicated that CLA could inhibit platelet deposition, decrease macrophage accumulation
and expression of the macrophage scavenger receptor CD36 in the aorta, and increase apoptosis
in atherosclerotic lesions, and thus exert a pre-resolving effect on atherosclerosis [86]. Increased
expression of peroxisome proliferators-activated receptor α (PPARα) and PPARγ by CLA may be one
possible mechanism for its protective effects against atherosclerosis [86]. CLA could also suppress
monocyte adhesion in vitro by targetting β2 integrin expression [87]. This may be another mechanism
for the anti-atherosclerotic effect of CLA. CLA (mixture of cis-9,trans-11 CLA and trans-10,cis-12
CLA) decreased pro-inflammatory cytokines (including IL-1β, IL-6, and TNFα) expression in
mammary epithelial cells treated with LPS by inhibiting reactive oxygen species (ROS) production
and up-regulating PPARγ expression [88]. A PPARγ-dependent anti-inflammatory effect of CLA was
also observed in mice with inflammatory bowel disease [89]. Moreover, reducing pro-inflammatory
eicosanoids release by inhibiting COX expression is also involved in the regulatory effect of CLA on
inflammatory responses [90,91]. In addition, CLA could inhibit high glucose-induced hypertrophy and
contractile dysfunction in adult rat cardiomyocytes by modulating PPARγ activation [92]. However,
an unfavorable effect on cardiometabolic health was also observed: high dose of CLA supplementation
increased insulin resistance in rats fed either a low fat or a high fat diet [93].
4.2.3. Brief Summary
Although favorable effects of CLA on cardiometabolic health have been observed in animal
studies and an observational study in humans, there is little evidence from RCTs, which supports
this opinion, and several RCTs even reported unfavorable results concerning lipid peroxidation and
inflammation. However, few intervention studies in humans have been conducted to evaluate the
direct effect of CLA on risk of CVD. Well-designed RCTs should be conducted to clarify this point.
4.3. CLNA and Cardiometabolic Health
4.3.1. Evidence from Human Studies
Favorable effects of CLNA on lipid metabolism were observed in one RCT: pomegranate seed
oil supplementation (rich in punicic acid (cis-9,trans-11,cis-13 CLNA)) significantly lowered serum
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TAG, the ratios of TAG to HDLC and TC to HDLC, and increased serum HDLC in hyperlipidemic
subjects [94]. No studies in humans have evaluated the association between CLNA and CVD or other
risk factors.
4.3.2. Evidence from Animal and in Vitro Studies
α-eleostearic acid (cis-9,trans-11,trans-13 CLNA) supplementation significantly lowered blood
TAG level in diabetic rats [95]. Pomegranate seed oil supplementation, which is rich in punicic acid
(cis-9,trans-11,cis-13 CLNA), significantly lowered TC in broilers [96]. Punicic acid (cis-9,trans-11,cis-13
CLNA) also significantly decreased ApoB100 secretion by human HepG2 cell in vitro [97]. ApoB100 is
the essential component of very-low density lipoproteins and positively correlated with the incidence
of coronary heart disease and atherosclerosis [97]. Bitter gourd oil supplementation, which is rich
in α-eleostearic acid (cis-9,trans-11,trans-13 CLNA), decreased blood level of free cholesterol and
increased HDLC in rats [98]. Several animal and in vitro studies reported the antioxidative effect
of CLNA. Results from an animal study indicated that α-eleostearic acid (cis-9,trans-11,trans-13
CLNA) supplementation could significantly lower LDL-lipid peroxidation and erythrocyte membrane
lipid peroxidation in diabetic rats [95]. One in vitro study also demonstrated that both punicic
acid (cis-9,trans-11,cis-13 CLNA) and α-eleostearic acid (cis-9,trans-11,trans-13 CLNA) could more
effectively scavenge hydroxyl radical and inhibit lipid peroxidation at lower concentrations than at
higher concentrations [99]. Another animal study compared the antioxidant effect of punicic acid
(cis-9,trans-11,cis-13 CLNA) and α-eleostearic acid (cis-9,trans-11,trans-13 CLNA) in rats, and found
that both could effectively decrease oxidative stress and lipid peroxidation induced by sodium arsenite;
the antioxidant effect of α-eleostearic acid was more potent than that of punicic acid [100]. However,
contradictory results concerning the antioxidative effect of CLNA was observed in another animal
study: supplementation of bitter gourd oil (rich in α-eleostearic acid (cis-9,trans-11,trans-13 CLNA))
significantly increased plasma hydroperoxides level [98]. One animal study evaluated the antioxidative
effect of punicic acid at different dose, and found punicic acid could act as both pro-oxidant (dose as
1.2% in total fatty acids) and antioxidant (dose as 0.6% in total fatty acids) [101]. Therefore, differences
in dose may help explain the inconsistent results concerning antioxidative effects of CLNA observed
in previous studies. In addition, CLNA also has an anti-inflammatory effect. Intake of pomegranate
seed oil (rich in punicic acid (cis-9,trans-11,cis-13 CLNA)) effectively inhibited neutrophil-activation
and protected against trinitrobenzene sulfonic acid (TNBS)-induced colon inflammation in rats; the
mechanism involved inhibiting TNF-α induced priming of NADPH oxidase and myeloperoxidase
release [102]. One study reported that α-eleostearic acid (cis-9,trans-11,trans-13 CLNA) ameliorated
inflammatory bowel disease in mice by activating PPARγ [103]. Down-regulating pro-inflammatory
cytokines expression, COX expression and NF-κB signal pathway are potential mechanisms for the
anti-inflammatory effects of CLNA [104,105].
4.3.3. Brief Summary
CLNA may have a favorable effect on cardiometabolic health, but evidence from human studies
is still very limited, and well-designed RCTs should be conducted to evaluate the effect of CLNA
supplementation on CVD and its risk factors.
5. Conclusions and Perspectives
DPA has a favorable effect on cardiometabolic health in a different way to the other LC n-3 PUFAs,
such as EPA and DHA. Furan fatty acids and CLNA may be potential bioactive components beneficial
for cardiometabolic health, but evidence from intervention studies in humans is still limited, and
well-designed clinical trials will be required. The favorable effects of CLA on cardiometabolic health
observed in animals or in vitro have not been replicated in most studies of humans. However, most
intervention studies in humans concerning CLA have only evaluated its effect on cardiometabolic risk
factors but not its direct effect on risk of CVD, and RCTs with large sample size are still required to
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clarify this point. Several difficulties and limitations exist for conducting RCTs to evaluate the effect of
these fatty acids on cardiometabolic health, especially the high cost of purifying these fatty acids from
natural sources because they occur at low levels in natural oils or foods.
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